MuriGenics offers and delivers robust preclinical in-vivo and in-vitro contract drug discovery and development services, supported with statistical validation, solid science and project management to companies throughout the United States.
Our growth is driven by repeat customers who recognize that MuriGenics delivers on-time, quality results. Our lead scientists bring over 50 years of experience and expertise to the table. In the past year, our scientific team has specialized in developing protocols, integrating in-vivo and in-vitro assays for our clients. Such innovation has minimized use of resources while maximizing information obtained from a single study.
We specialize in disease models for oncology, cardiovascular, inflammation and metabolic diseases. Please inquire about any additional models.
Henry Lopez – President and CSO
Formerly, Director of Phenotyping at Pfizer Global Research Alameda CA.; Director of Phenotyping Park Davis Laboratory for Molecular Genetics; Manager Physiology Department Glycomed
Steven Noonan – Chief Operations Officer (COO)
Formerly, COO of Phenomic Imaging; Scientist at Pfizer; Scientist at Parke-Davis
Scientific Advisors & Consultants
Donna Bouley D.V.M. Pathologist
Tim Doherty D.V.M. Laboratory Animal Medicine
David B. West Ph.D. Molecular and Cell Biology/Genetics
Edward H. Conrad Ph.D. Biochemist
Eric Memarzadeh Ph.D. Formulation Specialist
John Fidler Ph.D. Pharmacologist
John Musser Ph.D. Medicinal Chemist
Dan Levy, Ph.D. Organic Chemist www.delbiopharma.com
Kristin Evans, D.V.M. Laboratory Animal Medicine